BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home » Newsletters » BioWorld

BioWorld

July 15, 2013

View Archived Issues

Mitsubishi Tanabe Pharma Acquires Medicago for $357M

Osaka, Japan-based Mitsubishi Tanabe Pharma Corp. moved to acquire Canadian vaccine developer Medicago Inc. for $357 million, or $1.16 in cash per share, a premium of about 22.1 percent to the closing price of Medicago's stock on July 11. The acquisition follows a successful strategic alliance in 2012, under which the companies agreed to develop and commercialize at least three vaccines using Medicago's virus-like particle (VLP) technology. Read More

Lilly Reloads Solanezumab, Shoots for Mild Alzheimer's

As promised, Eli Lilly and Co. is making another run at Alzheimer's disease (AD) with its Phase III candidate solanezumab (sola), this time in the mild form of the disease. Read More

Antibodies Could be Basis for Improved Autism Diagnoses

Maternal antibodies protect children from infections before birth. But in some instances, they can also do damage. Read More

BI's Gilotrif Latest Success for Companion Diagnostics Space

Qiagen NV's Therascreen EGFR RGQ PCR Kit gained FDA approval alongside Boehringer Ingelheim GmbH's lung cancer drug Gilotrif (afatinib), putting another notch in the win column for the growing companion diagnostics space, though there are still challenges to overcome before the use of companion diagnostics becomes routine in the marketplace. Read More

Financings Roundup

• Amarin Corp. plc, of Dublin, completed its underwritten public offering of 21.7 million American Depositary Shares (ADS). The underwriters purchased the shares from the company at $5.60 apiece, for net proceeds of approximately $121.1 million. Read More

Stock Movers

Read More

Other News To Note

• Neostem Inc., of New York, disclosed a 1-for-10 reverse split of its common stock (NYSE:NBS), effective when trading begins on July 16. The company's ticker symbol will remain unchanged. Read More

Clinic Roundup

• Rxi Pharmaceuticals Corp., of Westborough, Mass., reported positive results of a Phase I study of RXI-109, an sd-rxRNA, for abnormal dermal scars. Read More

Pharma: Other News To Note

• Actavis Inc., of Parsippany, N.J., said it received approval from the FDA on its abbreviated new drug application for oxymorphone hydrochloride extended-release tablets at dosages of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. Read More

Bench Press: BioWorld Looks at Translational Medicine

RNA binding proteins are key to determining what ultimately happens to RNA after it is transcribed from DNA, influencing translation levels, splicing and other factors. But comparatively little is known about which sequences such proteins latch onto. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing